Kytril

Granisetron, the active ingredient in Kytril, is a 5-HT3 receptor antagonist presented as an injection for intravenous use. It prevents chemotherapy‑induced and postoperative nausea and vomiting in patients receiving such treatments.

GNH USA supplies Kytril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Kytril (granisetron) is used to control nausea and vomiting mediated by serotonin receptors.

- Chemotherapy‑induced nausea and vomiting: prevents and reduces episodes in patients receiving emetogenic chemotherapy. - Postoperative nausea and vomiting: reduces the incidence after surgical procedures. - Radiation therapy‑induced nausea and vomiting: helps control symptoms in patients undergoing radiotherapy.

Granisetron may cause adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate headache. - Constipation: reduced bowel movements. - Dizziness: feeling of light‑headedness. - Fatigue: general tiredness. - Flushing: transient skin redness.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm, especially in patients with pre‑existing conditions. - Severe allergic reaction: rash, swelling, difficulty breathing. - Serotonin syndrome: rare but potentially life‑threatening when combined with serotonergic agents. - Seizure: rare occurrence of convulsions.

Before administering Kytril, consider the following precautions.

- Assess cardiac history: monitor ECG in patients with known QT prolongation risk. - Review concomitant serotonergic drugs: avoid or monitor for serotonin syndrome. - Evaluate hepatic function: dose may need adjustment in severe impairment. - Consider pregnancy status: use only if benefits outweigh risks. - Monitor for allergic reactions: discontinue if severe hypersensitivity occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Granisetron can interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Other 5‑HT3 antagonists: additive antiemetic effect not required. - Cisapride: increased risk of QT prolongation. - Certain antiarrhythmics (e.g., quinidine, amiodarone): may exacerbate cardiac conduction abnormalities.

Moderate Interactions (Monitor Closely): - Serotonergic agents (SSRIs, SNRIs, tramadol): risk of serotonin syndrome. - CYP3A4 inhibitors (ketoconazole, erythromycin): may increase granisetron plasma levels. - CYP3A4 inducers (rifampin, carbamazepine): may reduce efficacy.